Keyphrases
5-year Survival
15%
Adjuvant Chemotherapy
38%
Advanced Laryngeal Cancer
22%
Ashkenazi Jews
16%
Breast Cancer Patients
31%
Breast Carcinoma
18%
Carcinoma
27%
Chemotherapy
51%
Cisplatin
16%
Clinical Course
16%
Complete Response
18%
Consecutive Patients
19%
Disease-free Interval
18%
Disease-free Survival
39%
Estrogen Receptor
27%
High Incidence
15%
Histological Subtypes
15%
Hormonal Therapy
19%
Hormone Receptor-positive
22%
Induction Chemotherapy
22%
Irradiation
20%
Israel
33%
Kaposi Sarcoma
40%
Leucovorin
14%
Locally Advanced Breast Cancer
27%
Locoregional
24%
Lymphoma
21%
Malignant Lymphoma
27%
Malignant Melanoma
14%
Medical Center
43%
Multivariate Analysis
32%
Nodal Status
31%
Non-Hodgkin Lymphoma
27%
Old Age
15%
Overall Survival
25%
Post-chemotherapy
27%
Progesterone Receptor
18%
Prognostic Factors
81%
Rabin
38%
Radiation Therapy
45%
Radiochemotherapy
16%
Radiotherapy
37%
Recurrent Disease
22%
Response to Treatment
18%
Retrospective Analysis
18%
Serum Levels
18%
T Stage
14%
Tumor
27%
Tumor Marker
20%
Univariate Analysis
22%
Medicine and Dentistry
Adjuvant Chemotherapy
33%
Breast Cancer
40%
Breast Carcinoma
16%
Carcinogenesis
13%
Carcinoma
27%
Cervical Cancer
13%
Chemoradiotherapy
13%
Cisplatin
13%
Clinical Guideline
13%
Clinical Study
13%
Colorectal Carcinoma
13%
Disease Course
18%
Disease Free Survival
31%
Diseases
63%
Estrogen Receptor
13%
Factor Analysis
13%
Gastric Lymphoma
13%
Hormone Therapy
23%
Induction Chemotherapy
21%
Kaposi Sarcoma
40%
Laryngeal Cancer
40%
Larynx Carcinoma
13%
Leiomyosarcoma
13%
Locally Advanced Breast Cancer
27%
Lymphoblastic Lymphoma
13%
Male Breast
13%
Melanoma
14%
Merkel Cell Carcinoma
13%
Multivariate Analysis
31%
Nasopharynx
13%
Neck
14%
Neoplasm
80%
Non Small Cell Lung Cancer
13%
Non-Hodgkin Lymphoma
20%
Ovarian Cancer
13%
Overall Survival
32%
Paraaortic Lymph Node
13%
Pleura Effusion
13%
Primary Tumor
14%
Prognostic Factor
81%
Radiation Therapy
100%
Receptor
18%
Recurrent Disease
38%
Retrospective Study
13%
Skin Cancer
13%
Survival Rate
25%
Systemic Therapy
13%
Tumor Marker
27%
Univariate Analysis
19%
Vagina Mucosa
13%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha Interferon
13%
Bone Marrow Toxicity
6%
Breast Cancer
27%
Carcinoembryonic Antigen
5%
Carcinogenesis
13%
Carcinoma
27%
Chemoradiation Therapy
13%
Chemotherapy
83%
Cisplatin
16%
Clinical Trial
13%
Colorectal Carcinoma
27%
Disease Exacerbation
10%
Disease Free Survival
22%
Diseases
65%
Estrogen Receptor
13%
Fluoropyrimidine
6%
Fluorouracil
9%
Folinic Acid
20%
Granulocyte Macrophage Colony Stimulating Factor
13%
Hyperthermia
13%
Isoniazid
6%
Kaposi Sarcoma
13%
Larynx Cancer
22%
Larynx Carcinoma
13%
Leukoencephalopathy
13%
Liver Disease
6%
Liver Metastasis
13%
Melanoma
14%
Merkel Cell Carcinoma
13%
Metastatic Melanoma
13%
Methotrexate
18%
Neoplasm
57%
Neutropenia
6%
Non Small Cell Lung Cancer
13%
Nonhodgkin Lymphoma
9%
Nuclear Estrogen
13%
Ovary Cancer
13%
Overall Survival
11%
Polypeptide
13%
Porphobilinogen Deaminase
13%
Primary Tumor
17%
Progesterone
9%
Progesterone Receptor
13%
Receptor
8%
Recurrent Disease
35%
Remission
11%
Retrospective Study
13%
Skin Cancer
13%
Survival Rate
21%
Systemic Treatment
13%